phenobarbital has been researched along with Unverricht-Lundborg Syndrome in 1 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Unverricht-Lundborg Syndrome: An autosomal recessive condition characterized by recurrent myoclonic and generalized seizures, ATAXIA, slowly progressive intellectual deterioration, DYSARTHRIA, and intention tremor. Myoclonic seizures are severe and continuous, and tend to be triggered by movement, stress, and sensory stimuli. The age of onset is between 8 and 13 years, and the condition is relatively frequent in the Baltic region, especially Finland. (From Menkes, Textbook of Child Neurology, 5th ed, pp109-110)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kälviäinen, R | 1 |
Genton, P | 1 |
Andermann, E | 1 |
Andermann, F | 1 |
Magaudda, A | 1 |
Frucht, SJ | 1 |
Schlit, AF | 1 |
Gerard, D | 1 |
de la Loge, C | 1 |
von Rosenstiel, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht[NCT00357669] | Phase 3 | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht[NCT00368251] | Phase 3 | 56 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Intervention | Percent change (Median) |
---|---|
Placebo | 17.45 |
Brivaracetam 5 mg/Day | -4.60 |
Brivaracetam 150 mg/Day | 12.34 |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Intervention | Percent change (Median) |
---|---|
Placebo | 0.00 |
Brivaracetam 5 mg/Day | 0.00 |
Brivaracetam 150 mg/Day | 0.00 |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Intervention | Percent change (Median) |
---|---|
Placebo | -9.68 |
Brivaracetam 5 mg/Day | 0.00 |
Brivaracetam 150 mg/Day | 5.41 |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Intervention | Percent change (Median) |
---|---|
Placebo | 0.00 |
Brivaracetam 5 mg/Day | 43.44 |
Brivaracetam 150 mg/Day | 0.00 |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
Brivaracetam 150 mg/Day | 11.1 | 11.1 | 33.3 | 33.3 | 5.6 | 5.6 | 0 |
Brivaracetam 5 mg/Day | 10.0 | 0 | 30.0 | 50.0 | 10.0 | 0 | 0 |
Placebo | 0 | 11.1 | 33.3 | 50.0 | 0 | 0 | 5.6 |
1 trial available for phenobarbital and Unverricht-Lundborg Syndrome
Article | Year |
---|---|
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |